Tests wearable digital measures during sulforaphane treatment for autism
Tests whether wearable devices can track changes in autism symptoms during sulforaphane.
Plain-language title generated from the registry record
Registry title: Validation Digital Bio-markers During Sulforaphane Treatment.
Key facts
- Where
- Piscataway, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 13 and 30 years old?
Source: NCT04805957, who can take part
Where in United States
- Rutgers-RWJMS Department of NeurologyPiscataway, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Rutgers, The State University of New Jersey
- Trial code
- NCT04805957
- Record updated
- 30 October 2025
- Original description
The purpose of the research is to determine if changes seen during sulforaphane treatment (a compound that comes from eating certain vegetables) can better be understood using digital biomarkers. These digital biomarkers are things like heart rate, muscle movement etc. and are measured using non-invasive devices (like a watch) and are aimed at complementing the traditional clinical scores already in use in current trials (e.g. Aberrant Behavior Checklist (ABC), Social Responsiveness Scale (SRS) and Ohio Autism Clinical Impressions Scale (OACIS)).Read full original descriptionShow less
A Pilot Project to Validate Digital Bio-markers as a Tool to Measure Improvement in Core Symptoms of Autism During Sulforaphane Treatment.
The purpose of the research is to determine if changes seen during sulforaphane treatment (a compound that comes from eating certain vegetables) can better be understood using digital biomarkers. These digital biomarkers are things like heart rate, muscle movement etc. and are measured using non-invasive devices (like a watch) and are aimed at complementing the traditional clinical scores already in use in current trials (e.g. Aberrant Behavior Checklist (ABC), Social Responsiveness Scale (SRS) and Ohio Autism Clinical Impressions Scale (OACIS)).
Inclusion: Autistic disorder diagnosis; Age between 13-30 years; Male gender; Participated in clinical trial NCT02677051.
Exclusion: Current infection or treatment with antibiotics; Chronic medical disorder (e.g., cardiovascular disease, stroke or diabetes) or major surgery within 3 months prior to enrollment; Seizure within 2 years of screening,; History of chronic kidney, liver or thyroid disease; A diagnosis of autism spectrum disorder other than autistic disorder, for example, Asperger, PDD-NOS ( Pervasive Developmental Disorder-Not Otherwise Specified) etc; Impaired renal function (serum creatinine> 1.2 mg/dl); Less than 13 years or more than 30 years of age; Those that started or continued taking Avmacol® or similar broccoli extracts since leaving our double-blind study; Absence of a parent or legal guardian and consent,; Those that can not or will not complete all visits and adherence to study regimen; Impaired hepatic function (> 2x upper limit of normal); Impaired thyroid function (TSH outside normal limits); Female gender.